{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:27:59Z","timestamp":1794745679037,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1465-9921-15-78","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:18:14Z","timestamp":1548202694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Safety and tolerability of once-daily umeclidinium\/vilanterol 125\/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"15","author":[{"given":"James F","family":"Donohue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Niewoehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, ATS\/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004, 23: 932-946. 10.1183\/09031936.04.00014304.","journal-title":"Eur Respir J"},{"key":"1516_CR2","volume-title":"Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease","author":"GOLD","year":"2014","unstructured":"GOLD: Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. 2014, [\n                    http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report2014_Feb07.pdf\n                    \n                  ]"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1183\/09059180.00009902","volume":"15","author":"V Brusasco","year":"2006","unstructured":"Brusasco V: Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev. 2006, 15: 32-36. 10.1183\/09059180.00009902.","journal-title":"Eur Respir Rev"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","volume":"23","author":"M Cazzola","year":"2010","unstructured":"Cazzola M, Molimard M: The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010, 23: 257-267. 10.1016\/j.pupt.2010.03.003.","journal-title":"Pulm Pharmacol Ther"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","volume":"67","author":"DA Mahler","year":"2012","unstructured":"Mahler DA, D\u2019Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B, INTRUST-1 and INTRUST-2 study investigators: Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012, 67: 781-788. 10.1136\/thoraxjnl-2011-201140.","journal-title":"Thorax"},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","volume":"21","author":"T van der Molen","year":"2012","unstructured":"van der Molen T, Cazzola M: Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012, 21: 101-108. 10.4104\/pcrj.2011.00102.","journal-title":"Prim Care Respir J"},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/thx.2010.139113","volume":"65","author":"JA van Noord","year":"2010","unstructured":"van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T: QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010, 65: 1086-1091. 10.1136\/thx.2010.139113.","journal-title":"Thorax"},{"key":"1516_CR8","first-page":"527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T: Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012, 18: 527-539.","journal-title":"J Manag Care Pharm"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.rmed.2012.03.012","volume":"106","author":"JF Donohue","year":"2012","unstructured":"Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G: A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012, 106: 970-979. 10.1016\/j.rmed.2012.03.012.","journal-title":"Respir Med"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1378\/chest.11-2231","volume":"142","author":"NA Hanania","year":"2012","unstructured":"Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Lettis S, Barnhart F, Haumann B: The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012, 142: 119-127. 10.1378\/chest.1388838.","journal-title":"Chest"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"J Donohue","year":"2013","unstructured":"Donohue J, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A: Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD. Respir Med. 2013, 107: 1538-1546. 10.1016\/j.rmed.2013.06.001.","journal-title":"Respir Med"},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1378\/chest.13-1579","volume":"145","author":"B Celli","year":"2014","unstructured":"Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A: Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study. Chest. 2014, 145: 981-991. 10.1378\/chest.13-1579.","journal-title":"Chest"},{"key":"1516_CR13","volume-title":"ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1)","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"1996","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). 1996, [\n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf\n                    \n                  ]"},{"key":"1516_CR14","volume-title":"WMA Declaration of Helsinki - ethical principles for medical research involving human subjects","author":"World Medical Association","year":"2008","unstructured":"World Medical Association: WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. 2008, [\n                    http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html\n                    \n                  ]"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","volume":"159","author":"JL Hankinson","year":"1999","unstructured":"Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999, 159: 179-187. 10.1164\/ajrccm.159.1.9712108.","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR16","doi-asserted-by":"crossref","first-page":"A1482","DOI":"10.1164\/rccm.201208-1414OC","volume":"187","author":"N Hanania","year":"2013","unstructured":"Hanania N, Donohue J, Make B: A long term safety study of arformoterol tartrate in the maintenance therapy of patients with moderate to severe COPD: incidence of adverse events. Am J Respir Crit Care Med. 2013, 187: A1482-","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1753465808089455","volume":"2","author":"JF Donohue","year":"2008","unstructured":"Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP: Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008, 2: 37-48. 10.1177\/1753465808089455.","journal-title":"Ther Adv Respir Dis"},{"key":"1516_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1753465808093934","volume":"2","author":"JF Donohue","year":"2008","unstructured":"Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehard M, Denis-Mize K: Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008, 2: 199-208. 10.1177\/1753465808093934.","journal-title":"Ther Adv Respir Dis"},{"key":"1516_CR19","first-page":"A1481","volume":"187","author":"B Make","year":"2013","unstructured":"Make B, Hanania N, Donohue J: A long term safety study of arformoterol tartrate in the maintenance therapy of patients with moderate to severe COPD: evaluation of lung function. Am J Respir Crit Care Med. 2013, 187: A1481-","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR20","first-page":"A2436","volume":"187","author":"J Donohue","year":"2013","unstructured":"Donohue J, Hanania N, Make B, Curry L: A long term safety study of arformoterol tartrate in the maintenance therapy of patients with moderate to severe COPD: incidence of respiratory-related deaths and COPD exacerbation-related hospitalizations. Am J Respir Crit Care Med. 2013, 187: A2436-","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1183\/09031936.02.00269802","volume":"19","author":"R Casaburi","year":"2002","unstructured":"Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002, 19: 217-224. 10.1183\/09031936.02.00269802.","journal-title":"Eur Respir J"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1378\/chest.10-1830","volume":"140","author":"KR Chapman","year":"2011","unstructured":"Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, INDORSE Study Investigators: Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011, 140: 68-75. 10.1378\/chest.10-1830.","journal-title":"Chest"},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1378\/chest.115.4.957","volume":"115","author":"DA Mahler","year":"1999","unstructured":"Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999, 115: 957-965. 10.1378\/chest.115.4.957.","journal-title":"Chest"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A: Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24\u00a0weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014, 2: 472-486. 10.1016\/S2213-2600(14)70065-7.","journal-title":"Lancet Respir Med"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.2165\/11318580-000000000-00000","volume":"69","author":"SR Salpeter","year":"2009","unstructured":"Salpeter SR: Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?. Drugs. 2009, 69: 2025-2033. 10.2165\/11318580-000000000-00000.","journal-title":"Drugs"},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1164\/rccm.2110093","volume":"166","author":"NR Anthonisen","year":"2002","unstructured":"Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group: Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002, 166: 333-339. 10.1164\/rccm.2110093.","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR27","volume-title":"FDA Briefing Document","author":"Division of Pulmonary-Allergy Drugs Advisory Committee and Office of Surveillance and Epidemiology, US Food and Drug Administration","year":"2009","unstructured":"Division of Pulmonary-Allergy Drugs Advisory Committee and Office of Surveillance and Epidemiology, US Food and Drug Administration: FDA Briefing Document. 2009, [\n                    http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/pulmonary-allergydrugsadvisorycommittee\/ucm190463.pdf\n                    \n                  ]"},{"key":"1516_CR28","volume-title":"Medical reviews, aclidinium bromide","author":"Center for Drug Evaluation and Research (CDER)","year":"2012","unstructured":"Center for Drug Evaluation and Research (CDER): Medical reviews, aclidinium bromide. 2012, [\n                    http:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/nda\/2012\/202450Orig1s000MedR.pdf\n                    \n                  ]"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-15-78.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:24:34Z","timestamp":1548203074000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-15-78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1186\/1465-9921-15-78","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718489447.793532747","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]},"assertion":[{"value":"12 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"78"}}